Correlation of obesity and osteoporosis: Effect of fat mass on the determination of osteoporosis

Journal of Bone and Mineral Research

Volumn 23, Issue 1, 2008, Pages 17-29

  Zhao, Lan Juan ^a   Jiang, Hui ^b   Papasian, Christopher J ^a   Maulik, Dev ^a   Drees, Betty ^a   Hamilton, James ^a   Deng, Hong Wen ^a,b,c,d  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b HUNAN NORMAL UNIVERSITY   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

^d UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Correlation; Fat mass; Obesity; Osteoporosis

Indexed keywords

ADIPONECTIN; AMYLIN; AROMATASE; INSULIN; LEPTIN; PANCREAS HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREPTIN; RESISTIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADIPOCYTE; BODY FAT; BODY MASS; BONE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CORRELATION ANALYSIS; HUMAN; NONHUMAN; OBESITY; OSTEOBLAST; OSTEOPOROSIS; REVIEW;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ADIPOCYTES; ADIPONECTIN; ADIPOSE TISSUE; AMYLOID; AROMATASE; BONE DENSITY; CELL DIFFERENTIATION; FEMALE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR II; INTERLEUKIN-6; LEPTIN; MALE; OBESITY; OSTEOBLASTS; OSTEOPOROSIS; PEPTIDE FRAGMENTS; PPAR GAMMA; RESISTIN; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEINS;

EID: 37548998960     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.070813     Document Type: Review

References (188)

1. Khaodhiar L, McCowen KC, Blackburn GL 1999 Obesity and its comorbid conditions. Clin Cornerstone 2:17-31.
2. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL 1994 Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 272:205-211.
3. Seidell JC 1999 Obesity: A growing problem. Acta Paediatr Suppl 88:46-50.
4. National Center for Health Statistics 2004 National Center for Health Statistics Survey. Available online at www.cdc.gov/nchs/products/pubs/pubd/ hestats/obese/obse99.htm. Accessed May 2007.
5. Wolf AM, Colditz GA 1998 Current estimates of the economic cost of obesity in the United States. Obes Res 6:97-106.
6. Kopelman PG 2000 Obesity as a medical problem. Nature 404:635-643.
7. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS 2003 Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289:76-79.
8. Melton LJ III 2003 Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 18:1139-1141.
9. Melton LJ III 2001 The prevalence of osteoporosis: Gender and racial comparison. Calcif Tissue Int 69:179-181.
10. Faulkner KG, Cummings SR, Black D, Palermo L, Gluer CC, Genant HK 1993 Simple measurement of femoral geometry predicts hip fracture: The study of osteoporotic fractures. J Bone Miner Res 8:1211-1217.
11. Recker RR, Kimmel DB 1991 Changes in trabecular microstructure in osteoporosis occur with normal bone remodeling dynamics. J Bone Miner Res 6:S1;S225.
12. Schaffler MB, Choi K, Milgrom C 1995 Aging and matrix microdamage accumulation in human compact bone. Bone 17:521-525.
13. Ray NF, Chan JK, Thamer M, Melton LJ III 1997 Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation. J Bone Miner Res 12:24-35.
14. Spencer H, Kramer L 1986 NIH Consensus Conference: Osteoporosis. Factors contributing to osteoporosis. J Nutr 116:316-319.
15. Rosen CJ, Bouxsein ML 2006 Mechanisms of Disease: Is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2:35-43.
16. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM 1993 Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 341:72-75.
17. Melton LJ III, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL 1993 Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 8:1227-1233.
18. Felson DT, Zhang Y, Hannan MT, Anderson JJ 1993 Effects of weight and body mass index on bone mineral density in men and women: The Framingham study. J Bone Miner Res 8:567-573.
19. Marcus R, Greendale G, Blunt BA, Bush TL, Sherman S, Sherwin R, Wahner H, Wells B 1994 Correlates of bone mineral density in the postmenopausal estrogen/progestin interventions trial. J Bone Miner Res 9:1467-1476.
20. Mazess RB, Barden HS, Ettinger M, Johnston C, Dawson-Hughes B, Baran D, Powell M, Notelovitz M 1987 Spine and femur density using dual-photon absorptiometry in US white women. Bone Miner 2:211-219.
21. Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD, McClung M, Hosking D, Yates AJ, Christiansen C 1999 Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res 14:1622-1627.
22. Reid IR, Ames R, Evans MC, Sharpe S, Gamble G, France JT, Lim TM, Cundy TF 1992 Determinants of total body and regional bone mineral density in normal postmenopausal women - a key role for fat mass. J Clin Endocrinol Metab 75:45-51.
23. Reid IR, Plank LD, Evans MC 1992 Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J Clin Endocrinol Metab 75:779-782.
24. Reid IR 2002 Relationships among body mass, its components, and bone. Bone 31:547-555.
25. Ilich JZ, Skugor M, Hangartner T, Baoshe A, Matkovic V 1998 Relation of nutrition, body composition and physical activity to skeletal development: A cross-sectional study in preadolescent females. J Am Coll Nutr 17:136-147.
26. Sabatier JP, Guaydier-Souquieres G, Benmalek A, Marcelli C 1999 Evolution of lumbar bone mineral content during adolescence and adulthood: A longitudinal study in 395 healthy females 10-24 years of age and 206 premenopausal women. Osteoporos Int 9:476-482.
27. Khosla S, Atkinson EJ, Riggs BL, Melton LJ III 1996 Relationship between body composition and bone mass in women. J Bone Miner Res 11:857-863.
28. Douchi T, Oki T, Nakamura S, Ijuin H, Yamamoto S, Nagata Y 1997 The effect of body composition on bone density in pre-and postmenopausal women. Maturitas 27:55-60.
29. Douchi T, Yamamoto S, Oki T, Maruta K, Kuwahata R, Nagata Y 2000 Relationship between body fat distribution and bone mineral density in premenopausal Japanese women. Obstet Gynecol 95:722-725.
30. Chen Z, Lohman TG, Stini WA, Ritenbaugh C, Aickin M 1997 Fat or lean tissue mass: Which one is the major determinant of bone mineral mass in healthy postmenopausal women? J Bone Miner Res 12:144-151.
31. Reid IR, Ames RW, Evans MC, Sharpe SJ, Gamble GD 1994 Determinants of the rate of bone loss in normal postmenopausal women. J Clin Endocrinol Metab 79:950-954.
32. Riis BJ, Rodbro P, Christiansen C 1986 The role of serum concentrations of sex steroids and bone turnover in the development and occurrence of postmenopausal osteoporosis. Calcif Tissue Int 38:318-322.
33. Lau EM, Chan YH, Chan M, Woo J, Griffith J, Chan HH, Leung PC 2000 Vertebral deformity in Chinese men: Prevalence, risk factors, bone mineral density, and body composition measurements. Calcif Tissue Int 66:47-52.
34. De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P, McCloskey EV, Mellstrom D, Melton LJ III, Meunier PJ, Pols HA, Reeve J, Silman A, Tenenhouse A 2005 Body mass index as a predictor of fracture risk: A meta-analysis. Osteoporos Int 16:1330-1338.
35. Goulding A, Jones IE, Taylor RW, Williams SM, Manning PJ 2001 Bone mineral density and body composition in boys with distal forearm fractures: A dual-energy x-ray absorptiometry study. J Pediatr 139:509-515.
36. Mobley SL, Ha E, Landoll JD, Badenop-Sevens NE, Clairmont A, Goel P, Matkovic V 2005 Children with bone fragility fractures have reduced bone mineral areal density at the forarm and hip and higher percent body fat. J Bone Miner Res 20:S34.
37. Hsu YH, Venners SA, Terwedow HA, Feng Y, Niu T, Li Z, Laird N, Brain JD, Cummings SR, Bouxsein ML, Rosen CJ, Xu X 2006 Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. Am J Clin Nutr 83:146-154.
38. Blum M, Harris SS, Must A, Naumova EN, Phillips SM, Rand WM, Dawson-Hughes B 2003 Leptin, body composition and bone mineral density in premenopausal women. Calcif Tissue Int 73:27-32.
39. Janicka A, Wren TA, Sanchez MM, Dorey F, Kim PS, Mittelman SD, Gilsanz V 2007 Fat mass is not beneficial to bone in adolescents and young adults. J Clin Endocrinol Metab 92:143-147.
40. Zhao LJ, Liu YJ, Liu PY, Hamilton J, Recker RR, Deng HW 2007 Relationship of obesity with osteoporosis. J Clin Endocrinol Metab 92:1640-1646.
41. World Health Oraganization 1997 Obesity: Preventing and Managing the Global Epidemic. World Health Organization, Genvea, Switzerland.
42. Reid IR, Legge M, Stapleton JP, Evans MC, Grey AB 1995 Regular exercise dissociates fat mass and bone density in premenopausal women. J Clin Endocrinol Metab 80:1764-1768.
43. St Onge MP 2005 Dietary fats, teas, dairy, and nuts: Potential functional foods for weight control? Am J Clin Nutr 81:7-15.
44. Reid IR 1996 Therapy of osteoporosis: Calcium, vitamin D, and exercise. Am J Med Sci 312:278-286.
45. Zemel MB 2004 Role of calcium and dairy products in energy partitioning and weight management. Am J Clin Nutr 79:907S-912S.
46. Manson JE, Martin KA 2001 Postmenopausal hormone-replacement therapy. N Engl J Med 345:34-40.
47. Sorensen MB, Rosenfalck AM, Hojgaard L, Ottesen B 2001 Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obes Res 9:622-626.
48. Smith MR 2004 Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. J Urol 172:S52-S56.
49. de Gregorio LH, Lacativa PG, Melazzi AC, Russo LA 2006 Glucocorticoid-induced osteoporosis. Arq Bras Endocrinol Metabol 50:793-801.
50. Steinbuch M, Youket TE, Cohen S 2004 Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 15:323-328.
51. Gaillard D, Wabitsch M, Pipy B, Negrel R 1991 Control of terminal differentiation of adipose precursor cells by glucocorticoids. J Lipid Res 32:569-579.
52. Livingstone DE, Jones GC, Smith K, Jamieson PM, Andrew R, Kenyon CJ, Walker BR 2000 Understanding the role of glucocorticoids in obesity: Tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 141:560-563.
53. Tarquini B, Navari N, Perfetto F, Piluso A, Romano S, Tarquini R 1997 Evidence for bone mass and body fat distribution relationship in postmenopausal obese women. Arch Gerontol Geriatr 24:15-21.
54. Wajchenberg BL 2000 Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocr Rev 21:697-738.
55. Heiss CJ, Sanborn CF, Nichols DL, Bonnick SL, Alford BB 1995 Associations of body fat distribution, circulating sex hormones, and bone density in postmenopausal women. J Clin Endocrinol Metab 80:1591-1596.
56. Stewart KJ, Deregis JR, Turner KL, Bacher AC, Sung J, Hees PS, Tayback M, Ouyang P 2002 Fitness, fatness and activity as predictors of bone mineral density in older persons. J Intern Med 252:381-388.
57. Jankowska EA, Rogucka E, Medras M 2001 Are general obesity and visceral adiposity in men linked to reduced bone mineral content resulting from normal ageing? A population-based study. Andrologia 33:384-389.
58. Huang JS, Rietschel P, Hadigan CM, Rosenthal DI, Grinspoon S 2001 Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 15:975-982.
59. Afghani A, Goran MI 2006 Racial differences in the association of subcutaneous and visceral fat on bone mineral content in prepubertal children. Calcif Tissue Int 79:383-388.
60. Pluijm SM, Visser M, Smit JH, Popp-Snijders C, Roos JC, Lips P 2001 Determinants of bone mineral density in older men and women: Body composition as mediator. J Bone Miner Res 16:2142-2151.
61. Castro JP, Joseph LA, Shin JJ, Arora SK, Nicasio J, Shatzkes J, Raklyar I, Erlikh I, Pantone V, Bahtiyar G, Chandler L, Pabon L, Choudhry S, Ghadiri N, Gosukonda P, Muniyappa R, von-Gicyzki H, McFarlane SI 2005 Differential effect of obesity on bone mineral density in White, Hispanic and African American women: A cross sectional study. Nutr Metab (Lond) 2:9.
62. Zhao LJ, Liu YJ, Recker RR, Deng HW 2005 Genes decrease osteoporosis risk also decrease risk of obesity. J Bone Miner Res 20:S339.
63. Young D, Hopper JL, Macinnis RJ, Nowson CA, Hoang NH, Wark JD 2001 Changes in body composition as determinants of longitudinal changes in bone mineral measures in 8 to 26-year-old female twins. Osteoporos Int 12:506-515.
64. Wearing SC, Hennig EM, Byrne NM, Steele JR, Hills AP 2006 Musculoskeletal disorders associated with obesity: A biomechanical perspective. Obes Rev 7:239-250.
65. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H 2004 PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113:846-855.
66. Gregoire FM, Smas CM, Sul HS 1998 Understanding adipocyte differentiation. Physiol Rev 78:783-809.
67. Wade GN, Gray JM, Bartness TJ 1985 Gonadal influences on adiposity. Int J Obes Relat Metab Disord 9(Suppl 1):83-92.
68. Cooke PS, Heine PA, Taylor JA, Lubahn DB 2001 The role of estrogen and estrogen receptor-alpha in male adipose tissue. Mol Cell Endocrinol 178:147-154.
69. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS 2000 Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci USA 97:12729-12734.
70. Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, Clyne CD, Davis S, Simpson ER, Carani C 2004 Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: Effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 89:61-70.
71. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS 1994 Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056-1061.
72. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K 1995 Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80:3689-3698.
73. Tchernof A, Calles-Escandon J, Sites CK, Poehlman ET 1998 Menopause, central body fatness, and insulin resistance: Effects of hormone-replacement therapy. Coron Artery Dis 9:503-511.
74. Riggs BL, Khosla S, Melton LJ III 1998 A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763-773.
75. Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, Kassem M 2001 Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2:165-171.
76. Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani AR 2001 Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas 39:125-132.
77. Jensen LB, Vestergaard P, Hermann AP, Gram J, Eiken P, Abrahamsen B, Brot C, Kolthoff N, Sorensen OH, Beck-Nielsen H, Nielsen SP, Charles P, Mosekilde L 2003 Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: A randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. J Bone Miner Res 18:333-342.
78. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321-333.
79. Okazaki R, Inoue D, Shibata M, Saika M, Kido S, Ooka H, Tomiyama H, Sakamoto Y, Matsumoto T 2002 Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology 143:2349-2356.
80. Seckl JR 2004 11beta-hydroxysteroid dehydrogenases: Changing glucocorticoid action. Curr Opin Pharmacol 4:597-602.
81. Seckl JR, Morton NM, Chapman KE, Walker BR 2004 Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 59:359-393.
82. Bujalska IJ, Kumar S, Stewart PM 1997 Does central obesity reflect "Cushing's disease of the omentum"? Lancet 349:1210-1213.
83. Liu Y, Sun WL, Sun Y, Hu G, Ding GX 2006 Role of 11beta-hydroxysteroid dehydrogenase type 1 in differentiation of 3T3-L1 cells and in rats with diet-induced obesity. Acta Pharmacol Sin 27:588-596.
84. Kannisto K, Pietilainen KH, Ehrenborg E, Rissanen A, Kaprio J, Hamsten A, Yki-Jarvinen H 2004 Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: Studies in young adult monozygotic twins. J Clin Endocrinol Metab 89:4414-4421.
85. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Heintze U, Janke J, Luft FC, Sharma AM 2004 Regulation of 11beta-HSD genes in human adipose tissue: Influence of central obesity and weight loss. Obes Res 12:9-17.
86. Draper N, Stewart PM 2005 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 186:251-271.
87. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ 1997 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94:14924-14929.
88. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR 2001 Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86:1418-1421.
89. Eijken M, Koedam M, van Driel M, Buurman CJ, Pols HA, van Leeuwen JP 2006 The essential role of glucocorticoids for proper human osteoblast differentiation and matrix mineralization. Mol Cell Endocrinol 248:87-93.
90. Cheng SL, Zhang SF, Avioli LV 1996 Expression of bone matrix proteins during dexamethasone-induced mineralization of human bone marrow stromal cells. J Cell Biochem 61:182-193.
91. Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M, Stewart PM 2002 Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 17:979-986.
92. Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M, Stewart PM 2000 Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone. Bone 27:375-381.
93. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM 2004 11beta-hydroxysteroid dehydrogenase type 1: A tissue-specific regulator of glucocorticoid response. Endocr Rev 25:831-866.
94. Cooper MS, Blumsohn A, Goddard PE, Bartlett WA, Shackleton CH, Eastell R, Hewison M, Stewart PM 2003 11beta-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone. J Clin Endocrinol Metab 88:3874-3877.
95. Eijken M, Hewison M, Cooper MS, de Jong FH, Chiba H, Stewart PM, Uitterlinden AG, Pols HA, van Leeuwen JP 2005 11beta-hydroxysteroid dehydrogenase expression and glucocorticoid synthesis are directed by a molecular switch during osteoblast differentiation. Mol Endocrinol 19:621-631.
96. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM 1994 Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432.
97. Friedman JM, Halaas JL 1998 Leptin and the regulation of body weight in mammals. Nature 395:763-770.
98. Wisse BE, Schwartz MW 2001 Role of melanocortins in control of obesity. Lancet 358:857-859.
99. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G 2005 Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434:514-520.
100. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G 2002 Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317.
101. Herzog H 2003 Neuropeptide Y and energy homeostasis: Insights from Y receptor knockout models. Eur J Pharmacol 480:21-29.
102. Liu YJ, Araujo S, Recker RR, Deng HW 2003 Molecular and genetic mechanisms of obesity: Implications for future management. Curr Mol Med 3:325-340.
103. Lin S, Boey D, Herzog H 2004 NPY and Y receptors: Lessons from transgenic and knockout models. Neuropeptides 38:189-200.
104. Sainsbury A, Schwarzer C, Couzens M, Fetissov S, Furtinger S, Jenkins A, Cox HM, Sperk G, Hokfelt T, Herzog H 2002 Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc Natl Acad Sci USA 99:8938-8943.
105. Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM, Herzog H 2002 Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 109:915-921.
106. Sainsbury A, Baldock PA. Schwarzer C, Ueno N, Enriquez RF, Couzens M, Inui A, Herzog H, Gardiner EM 2003 Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice. Mol Cell Biol 23:5225-5233.
107. Allison SJ, Baldock PA, Herzog H 2007 The control of bone remodeling by neuropeptide Y receptors. Peptides 28:320-325.
108. Mantzoros CS 1999 The role of leptin in human obesity and disease: A review of current evidence. Ann Intern Med 130:671-680.
109. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G 2000 Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 100:197-207.
110. Kontogianni MD, Dafni UG, Routsias JG, Skopouli FN 2004 Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res 19:546-551.
111. Pasco JA, Henry MJ, Kotowicz MA, Collier GR, Ball MJ, Ugoni AM, Nicholson GC 2001 Serum leptin levels are associated with bone mass in nonobese women. J Clin Endocrinol Metab 86:1884-1887.
112. Yamauchi M, Sugimoto T, Yamaguchi T, Nakaoka D, Kanzawa M, Yano S, Ozuru R, Sugishita T, Chihara K 2001 Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol (Oxf) 55:341-347.
113. Goulding A, Taylor RW 1998 Plasma leptin values in relation to bone mass and density and to dynamic biochemical markers of bone resorption and formation in postmenopausal women. Calcif Tissue Int 63:456-458.
114. Reid IR 2004 Leptin deficiency-lessons in regional differences in the regulation of bone mass. Bone 34:369-371.
115. Hamrick MW, Pennington C, Newton D, Xie D, Isales C 2004 Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 34:376-383.
116. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL 1999 Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140:1630-1638.
117. Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, Grey AB, Broom N, Myers DE, Nicholson GC, Reid IR 2002 Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 175:405-415.
118. Thomas T 2003 Leptin: A potential mediator for protective effects of fat mass on bone tissue. Joint Bone Spine 70:18-21.
119. Thomas T 2004 The complex effects of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol 4:295-300.
120. Thomas T, Burguera B 2002 Is leptin the link between fat and bone mass? J Bone Miner Res 17:1563-1569.
121. Martin A, de Vittoris R, David V, Moraes R, Begeot M, Lafage-Proust MH, Alexandre C, Vico L, Thomas T 2005 Leptin modulates both resorption and formation while preventing disuse-induced bone loss in tail-suspended female rats. Endocrinology 146:3652-3659.
122. Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG 2000 Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 92:73-78.
123. Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, Li L, Brancorsini S, Sassone-Corsi P, Townes TM, Hanauer A, Karsenty G 2004 ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell 117:387-398.
124. Fu L, Patel MS, Bradley A, Wagner EF, Karsenty G 2005 The molecular clock mediates leptin-regulated bone formation. Cell 122:803-815.
125. Karsenty G 2006 Convergence between bone and energy homeostases: Leptin regulation of bone mass. Cell Metab 4:341-348.
126. Asnicar MA, Smith DP, Yang DD, Heiman ML, Fox N, Chen YF, Hsiung HM, Koster A 2001 Absence of cocaine- and amphetamine-regulated transcript results in obesity in mice fed a high caloric diet. Endocrinology 142:4394-4400.
127. Cohen MM Jr 2006 Role of leptin in regulating appetite, neuroendocrine function, and bone remodeling. Am J Med Genet A 140:515-524.
128. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L 2001 Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108:1875-1881.
129. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE 2001 The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953.
130. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA 2001 Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935.
131. Lenchik L, Register TC, Hsu FC, Lohman K, Nicklas BJ, Freedman BI, Langefeld CD, Carr JJ, Bowden DW 2003 Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone 33:646-651.
132. Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, Syversen U, Reseland JE 2004 Adiponectin and its receptors are expressed in bone-forming cells. Bone 35:842-849.
133. Jurimae J, Rembel K, Jurimae T, Rehand M 2005 Adiponectin is associated with bone mineral density in perimenopausal women. Horm Metab Res 37:297-302.
134. Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, Yoshikawa H, Shimomura I 2005 Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 331:520-526.
135. Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP, Liao EY 2005 Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 309:99-109.
136. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS. Lazar MA 2001 The hormone resistin links obesity to diabetes. Nature 409:307-312.
137. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, Simon I, Soler J, Richart C 2004 Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: Relationships in obesity. Obes Res 12:962-971.
138. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS 2003 Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 88:1730-1736.
139. Thommesen L, Stunes AK, Monjo M, Grosvik K, Tamburstuen MV, Kjobli E, Lyngstadaas SP, Reseland JE, Syversen U 2006 Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem.
140. Oh KW, Lee WY, Rhee EJ, Baek KH, Yoon KH, Kang MI, Yun EJ, Park CY, Ihm SH, Choi MG, Yoo HJ, Park SW 2005 The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endocrinol (Oxf) 63:131-138.
141. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW 2004 Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145:2273-2282.
142. Fernandez-Real JM, Ricart W 2003 Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24:278-301.
143. Das UN 2001 Is obesity an inflammatory condition? Nutrition 17:953-966.
144. Berthier MT, Paradis AM, Tchernof A, Bergeron J, Prud'homme D, Despres JP, Vohl MC 2003 The interleukin 6-174G/C polymorphism is associated with indices of obesity in men. J Hum Genet 48:14-19.
145. Kershaw EE, Flier JS 2004 Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548-2556.
146. Richards CD, Langdon C, Deschamps P, Pennica D, Shaughnessy SG 2000 Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: Synergy with dexamethasone. Cytokine 12:613-621.
147. Rodan GA 1992 Introduction to bone biology. Bone 13(Suppl 1):S3-S6.
148. Dodds RA, Merry K, Littlewood A, Gowen M 1994 Expression of mRNA for IL1 beta, IL6 and TGF beta 1 in developing human bone and cartilage. J Histochem Cytochem 42:733-744.
149. Taguchi Y, Yamamoto M, Yamate T, Lin SC, Mocharla H, DeTogni P, Nakayama N, Boyce BF, Abe E, Manolagas SC 1998 Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Am Physicians 110:559-574.
150. Franchimont N, Wertz S, Malaise M 2005 Interleukin-6: An osteotropic factor influencing bone formation? Bone 37:601-606.
151. Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, Ernst M, Martin TJ 2004 Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest 113:379-389.
152. Barrett-Connor E, Kritz-Silverstein D 1996 Does hyperinsulinemia preserve bone? Diabetes Care 19:1388-1392.
153. Stolk RP, Van Daele PL, Pols HA, Burger H, Hofman A, Birkenhager JC, Lamberts SW, Grobbee DE 1996 Hyperinsulinemia and bone mineral density in an elderly population: The Rotterdam Study. Bone 18:545-549.
154. Tuominen JT, Impivaara O, Puukka P, Ronnemaa T 1999 Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 22:1196-1200.
155. Reda TK, Geliebter A, Pi-Sunyer FX 2002 Amylin, food intake, and obesity. Obes Res 10:1087-1091.
156. Roth JD, Hughes H, Kendall E, Baron AD, Anderson CM 2006 Anti-obesity effects of the {beta}-cell hormone amylin in diet induced obese rats: Effects on food intake, body weight, composition, energy expenditure and gene expression. Endocrinology 147:5855-5864.
157. Dacquin R, Davey RA, Laplace C, Levasseur R, Morris HA, Goldring SR, Gebre-Medhin S, Galson DL, Zajac JD, Karsenty G 2004 Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol 164:509-514.
158. Cornish J, Naot D 2002 Amylin and adrenomedullin: Novel regulators of bone growth. Curr Pharm Des 8:2009-2021.
159. Buchanan CM, Phillips AR, Cooper GJ 2001 Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion. Biochem J 360:431-439.
160. Cornish J, Callon KE, Bava U, Watson M, Xu X, Lin JM, Chan VA, Grey AB, Naot D, Buchanan CM, Cooper GJ, Reid IR 2007 Preptin, another peptide product fo the pancreatic {beta}-cell, is osteogenic in vitro and in vivo. Am J Physiol Endocrinol Metab 292:E117-E122.
161. Pei L, Tontonoz P 2004 Fat's loss is bone's gain. J Clin Invest 113:805-806.
162. Ross SE, Erickson RL, Gerin I, DeRose PM, Bajnok L, Longo KA, Misek DE, Kuick R, Hanash SM, Atkins KB, Andresen SM, Nebb HI, Madsen L, Kristiansen K, MacDougald OA 2002 Microarray analyses during adipogenesis: Understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor {alpha} in adipocyte metabolism. Mol Cell Biol 22:5989-5999.
163. Bennett CN, Ross SE, Longo KA, Bajnok L, Hemati N, Johnson KW, Harrison SD, MacDougald OA 2002 Regulation of Wnt signaling during adipogenesis. J Biol Chem 277:30998-31004.
164. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML 2001 LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523.
165. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML 2002 A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19.
166. Gimble JM, Zvonic S, Floyd ZE, Kassem M, Nuttall ME 2006 Playing with bone and fat. J Cell Biochem 98:251-266.
167. Gimble JM, Nuttall ME 2004 Bone and fat: Old questions, new insights. Endocrine 23:183-188.
168. Peptan IA, Hong L, Mao JJ 2006 Comparison of osteogenic potentials of visceral and subcutaneous adipose-derived cells of rabbits. Plast Reconstr Surg 117:1462-1470.
169. Wajchenberg BL, Giannella-Neto D, da Silva ME, Santos RF 2002 Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res 34:616-621.
170. Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM, Morris DC 1996 Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 50:1087-1094.
171. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL 2002 Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143:2376-2384.
172. Kirkland JL, Tchkonia T, Pirtskhalava T, Han J, Karagiannides I 2002 Adipogenesis and aging: Does aging make fat go MAD? Exp Gerontol 37:757-767.
173. Hotta K, Bodkin NL, Gustafson TA, Yoshioka S, Ortmeyer HK, Hansen BC 1999 Age-related adipose tissue mRNA expression of ADD1/SREBP1, PPARgamma, lipoprotein lipase, and GLUT4 glucose transporter in rhesus monkeys. J Gerontol A Biol Sci Med Sci 54:B183-B188.
174. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B 2004 Aging activates adipogeric and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: The role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 3:379-389.
175. Takada I, Suzawa M, Kato S 2005 Nuclear receptors as targets for drug development: Crosstalk between peroxisome proliferator-activated receptor gamma and cytokines in bone marrow-derived mesenchymal stem cells. J Pharmacol Sci 97:184-189.
176. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, MacDougald OA 2000 Inhibition of adipogenesis by Wnt signaling. Science 289:950-953.
177. Liu J, Farmer SR 2004 Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem 279:45020-45027.
178. Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, Hess F, Saint-Jeannet JP, He X 2000 LDL-receptor-related proteins in Wnt signal transduction. Nature 407:530-535.
179. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP 2002 High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521.
180. Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass DA II, Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L 2002 Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157:303-314.
181. Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PV, Robinson JA, Bhat B, Marzolf J, Moran RA, Bex F 2003 High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18:960-974.
182. Bodine PV, Komm BS 2006 Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord 7:33-39.
183. Locklin RM, Oreffo RO, Triffitt JT 1999 Effects of TGFbeta and bFGF on the differentiation of human bone marrow stromal fibroblasts. Cell Biol Int 23:185-194.
184. Bonewald LF, Dallas SL 1994 Role of active and latent transforming growth factor beta in bone formation. J Cell Biochem 55:350-357.
185. Centrella M, Horowitz MC, Wozney JM, McCarthy TL 1994 Transforming growth factor-beta gene family members and bone. Endocr Rev 15:27-39.
186. Zhou S, Lechpammer S, Greenberger JS, Glowacki J 2005 Hypoxia inhibition of adipocytogenesis in human bone marrow stromal cells requires transforming growth factor-beta/Smad3 signaling. J Biol Chem 280:22688-22696.
187. Zhou S, Eid K, Glowacki J 2004 Cooperation between TGF-beta and Wnt pathways during chondrocyte and adipocyte differentiation of human marrow stromal cells. J Bone Miner Res 19:463-470.
188. Minguell JJ, Erices A, Conget P 2001 Mesenchymal stem cells. Exp Biol Med (Maywood) 226:507-520.